Sun Pharmaceutical Industries is currently trading at Rs. 498.35, up by 8.90 points or 1.82% from its previous closing of Rs. 489.45 on the BSE.
The scrip opened at Rs. 494.25 and has touched a high and low of Rs. 498.35 and Rs. 492.45 respectively. So far 19073 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 564.90 on 28-Aug-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 528.45 and Rs. 483.00 respectively. The current market cap of the company is Rs. 119234.95 crore.
The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.
Sun Pharmaceutical Industries is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in the US market. The company's strategy of developing the specialty business as an additional growth engine has started delivering results, with a gradual ramp up in specialty revenues. The company expects this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: